Compare Bristol-Myers Squibb Co (BMY) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Stanley Black & Decker, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Stanley Black & Decker, Inc. trades at $103.91 (market cap $15.71B). The key difference: Bristol-Myers Squibb Co is far larger — about 8.3× Stanley Black & Decker, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | SWK | |
|---|---|---|
Market Cap | $129.94B | $15.71B |
Sector | Health | — |
52-Week High | $65.89 | $104.00 |
52-Week Low | $42.60 | $62.12 |
Enterprise Value | $163.92B | $19.87B |
Dividend Yield | 3.96% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Stanley Black & Decker (SWK) trades at $103.11, up 0.46% today, with a bullish technical signal from moving averages but overbought RSI readings near 80. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.57 exceeding expectations by 30%. Recent news highlights a $1 billion U.S. investment plan and strong institutional buying, while fundamentals show improving margins and debt reduction progress.
SWK presents a mixed outlook: positive earnings momentum and strategic initiatives support upside, but valuation appears stretched with a P/E of 25.4 above sector averages. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is cautious with a hold-heavy rating and $93.67 price target below current levels, suggesting limited near-term upside despite operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
